Survival advantage of coagulation factor XI-deficient mice during peritoneal sepsis

Erik Tucker, David Gailani, Sawan Hurst, Qiufang Cheng, Stephen R. Hanson, Andras Gruber

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Anticoagulation is a rational approach to the treatment of sepsis-associated consumptive coagulopathy, but its application is limited because of the risk of excessive bleeding. Factor XI (FXI) contributes substantially to pathological blood coagulation (thrombosis), whereas it contributes only modestly to normal hemostasis. We found that FXI-deficient mice have reduced coagulopathy and increased survival relative to FXI-expressing wild-type mice during cecal ligation and puncture-induced acute peritonitis/sepsis. This finding suggests that FXI contributes to coagulopathy and/or inflammation during sepsis and that pharmacologic inhibition of FXI activity may alter the course and outcome of some infections.

Original languageEnglish (US)
Pages (from-to)271-274
Number of pages4
JournalJournal of Infectious Diseases
Volume198
Issue number2
DOIs
StatePublished - Jul 15 2008

Fingerprint

Factor XI
Sepsis
Blood Coagulation
Hemostasis
Peritonitis
Punctures
Ligation
Thrombosis
Hemorrhage
Inflammation
Infection

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health
  • Immunology

Cite this

Survival advantage of coagulation factor XI-deficient mice during peritoneal sepsis. / Tucker, Erik; Gailani, David; Hurst, Sawan; Cheng, Qiufang; Hanson, Stephen R.; Gruber, Andras.

In: Journal of Infectious Diseases, Vol. 198, No. 2, 15.07.2008, p. 271-274.

Research output: Contribution to journalArticle

Tucker, Erik ; Gailani, David ; Hurst, Sawan ; Cheng, Qiufang ; Hanson, Stephen R. ; Gruber, Andras. / Survival advantage of coagulation factor XI-deficient mice during peritoneal sepsis. In: Journal of Infectious Diseases. 2008 ; Vol. 198, No. 2. pp. 271-274.
@article{337eda77cb014017a603034d78c02241,
title = "Survival advantage of coagulation factor XI-deficient mice during peritoneal sepsis",
abstract = "Anticoagulation is a rational approach to the treatment of sepsis-associated consumptive coagulopathy, but its application is limited because of the risk of excessive bleeding. Factor XI (FXI) contributes substantially to pathological blood coagulation (thrombosis), whereas it contributes only modestly to normal hemostasis. We found that FXI-deficient mice have reduced coagulopathy and increased survival relative to FXI-expressing wild-type mice during cecal ligation and puncture-induced acute peritonitis/sepsis. This finding suggests that FXI contributes to coagulopathy and/or inflammation during sepsis and that pharmacologic inhibition of FXI activity may alter the course and outcome of some infections.",
author = "Erik Tucker and David Gailani and Sawan Hurst and Qiufang Cheng and Hanson, {Stephen R.} and Andras Gruber",
year = "2008",
month = "7",
day = "15",
doi = "10.1086/589514",
language = "English (US)",
volume = "198",
pages = "271--274",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
publisher = "Oxford University Press",
number = "2",

}

TY - JOUR

T1 - Survival advantage of coagulation factor XI-deficient mice during peritoneal sepsis

AU - Tucker, Erik

AU - Gailani, David

AU - Hurst, Sawan

AU - Cheng, Qiufang

AU - Hanson, Stephen R.

AU - Gruber, Andras

PY - 2008/7/15

Y1 - 2008/7/15

N2 - Anticoagulation is a rational approach to the treatment of sepsis-associated consumptive coagulopathy, but its application is limited because of the risk of excessive bleeding. Factor XI (FXI) contributes substantially to pathological blood coagulation (thrombosis), whereas it contributes only modestly to normal hemostasis. We found that FXI-deficient mice have reduced coagulopathy and increased survival relative to FXI-expressing wild-type mice during cecal ligation and puncture-induced acute peritonitis/sepsis. This finding suggests that FXI contributes to coagulopathy and/or inflammation during sepsis and that pharmacologic inhibition of FXI activity may alter the course and outcome of some infections.

AB - Anticoagulation is a rational approach to the treatment of sepsis-associated consumptive coagulopathy, but its application is limited because of the risk of excessive bleeding. Factor XI (FXI) contributes substantially to pathological blood coagulation (thrombosis), whereas it contributes only modestly to normal hemostasis. We found that FXI-deficient mice have reduced coagulopathy and increased survival relative to FXI-expressing wild-type mice during cecal ligation and puncture-induced acute peritonitis/sepsis. This finding suggests that FXI contributes to coagulopathy and/or inflammation during sepsis and that pharmacologic inhibition of FXI activity may alter the course and outcome of some infections.

UR - http://www.scopus.com/inward/record.url?scp=47649108101&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=47649108101&partnerID=8YFLogxK

U2 - 10.1086/589514

DO - 10.1086/589514

M3 - Article

VL - 198

SP - 271

EP - 274

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

SN - 0022-1899

IS - 2

ER -